TNF Pharmaceuticals Files 8-K: Material Agreement & Bylaw Changes
Ticker: QCLS · Form: 8-K · Filed: Sep 10, 2025 · CIK: 1321834
| Field | Detail |
|---|---|
| Company | Tnf Pharmaceuticals, Inc. (QCLS) |
| Form Type | 8-K |
| Filed Date | Sep 10, 2025 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.001, $1,000, $5.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, corporate-governance, filing-update
TL;DR
TNF Pharma inked a big deal & changed some rules, filing an 8-K on 9/4/25.
AI Summary
On September 4, 2025, TNF Pharmaceuticals, Inc. (formerly MyMD Pharmaceuticals, Inc.) entered into a material definitive agreement. The company also made modifications to security holder rights and amended its articles of incorporation or bylaws. This filing also includes Regulation FD disclosures and financial statements.
Why It Matters
This 8-K filing indicates significant corporate actions by TNF Pharmaceuticals, including a new material agreement and changes affecting security holders, which could impact the company's strategic direction and shareholder value.
Risk Assessment
Risk Level: medium — Material definitive agreements and changes to security holder rights can introduce new risks or alter existing ones for investors.
Key Players & Entities
- TNF Pharmaceuticals, Inc. (company) — Registrant
- MyMD Pharmaceuticals, Inc. (company) — Former company name
- Akers Biosciences, Inc. (company) — Former company name
- September 4, 2025 (date) — Date of earliest event reported
- September 10, 2025 (date) — Filing date
FAQ
What is the nature of the material definitive agreement entered into by TNF Pharmaceuticals, Inc. on September 4, 2025?
The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the provided text.
What specific modifications were made to the rights of security holders?
The filing states that there were material modifications to the rights of security holders, but the exact nature of these modifications is not detailed in the provided text.
What are the key changes in the amended articles of incorporation or bylaws?
The filing mentions amendments to the articles of incorporation or bylaws, but the specific changes are not elaborated upon in the provided text.
When was TNF Pharmaceuticals, Inc. formerly known as MyMD Pharmaceuticals, Inc. and Akers Biosciences, Inc.?
TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. since April 20, 2021, and prior to that, as Akers Biosciences, Inc. since April 13, 2017, and Akers Biosciences Inc. since March 25, 2005.
What is the primary business of TNF Pharmaceuticals, Inc. according to its SIC code?
According to its Standard Industrial Classification (SIC) code [2835], TNF Pharmaceuticals, Inc. is involved in 'IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES'.
Filing Stats: 1,383 words · 6 min read · ~5 pages · Grade level 13.1 · Accepted 2025-09-10 17:00:34
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share TNFA The Nasdaq Capital M
- $1,000 — $0.001 per share and a stated value of $1,000 per share, initially convertible into u
- $5.00 — ock") at an initial conversion price of $5.00 per share and (ii) warrants to acquire
Filing Documents
- form8-k.htm (8-K) — 51KB
- ex3-1.htm (EX-3.1) — 321KB
- ex3-2.htm (EX-3.2) — 502KB
- ex3-3.htm (EX-3.3) — 338KB
- ex3-4.htm (EX-3.4) — 120KB
- ex99-1.htm (EX-99.1) — 13KB
- 0001641172-25-027052.txt ( ) — 1772KB
- tnfa-20250904.xsd (EX-101.SCH) — 3KB
- tnfa-20250904_lab.xml (EX-101.LAB) — 33KB
- tnfa-20250904_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TNF PHARMACEUTICALS, INC. Date: September 10, 2025 By: /s/ Joshua Silverman Joshua Silverman Executive Chairman